IRYS (IRYS) fluctuates 40.9% in 24 hours: trading volume surge triggers extreme price swings
Bitget Pulse2026/04/20 14:30Volatility Overview
In the past 24 hours, the price of IRYS rebounded from a low of $0.02616 to a high of $0.03685, currently quoted at $0.03678, with a fluctuation amplitude of 40.9%. Trading volume surged significantly. According to CoinGecko, 24-hour trading volume reached $28.9 million, up 422.7% from the previous day; CoinMarketCap reported $18.28 million, up 187.28%.
Brief Analysis of Abnormal Movements
• Trading volume surged 422.7% within 24 hours, causing extreme volatility, mainly reflected in sharp price spikes and dips in both spot and futures markets. Multiple short-term spikes over 3% were observed on Coinbase spot and Binance futures.
• No official announcements, on-chain whale transfers, or major news events were observed within the past 24 hours as drivers.
Market Sentiment and Outlook
Community sentiment remains optimistic, with 76% bullish votes on CoinMarketCap. Traders are focusing on the rebound potential from key support levels (such as $0.027-$0.029); if the price maintains or retests the $0.035 resistance, the bullish trend may continue. However, be cautious of short-term profit-taking and further tests of the $0.026 low. AI trading signals suggest waiting for confirmation of a reversal.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is for information reference only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Marvell Technology (MRVL.US) plummets after earnings: Beating forecasts is not enough—Wall Street thinks Google (GOOGL.US) orders are recognized too slowly
Although Marvell Technology's latest financial report and future revenue guidance both superficially exceeded market expectations, its stock price still plummeted in pre-market trading on Friday.

Gold prices could soar to $12,000 if US national debt keeps rising, says strategist
PURR stock hits record $14.15 as Hyperliquid revenue tops $718 million
From Lowering Blood Sugar and Weight Loss to Cardiovascular Protection! Mounjaro Achieves "Cardiometabolic Leap," Lilly (LLY.US) Opens GLP-1's Second Growth Curve
Eli Lilly's diabetes drug Mounjaro has received approval in the United States for reducing the risk of serious cardiovascular disease. The U.S. Food and Drug Administration has approved Mounjaro for lowering cardiovascular risk in adults with type 2 diabetes who have established heart disease.
